Paper Title
Development and validation of a new RP-HPLC Method for the simultaneous estimation of Lamivudine, Doravirine and Tenofovir disoproxil fumarate in combined dosage form
Article Identifiers
: Authors
Keywords
Key Words: Lamivudine, Doravirine, Tenofovir disoproxil fumarate, RP-HPLC, method development, validation.
Abstract
A new, simple, accurate and specific RP-HPLC method was developed for the simultaneous estimation of the Lamivudine, Doravirine and Tenofovir disoproxil fumarate in combined solid dosage form. The chromatogram was run through Kromasil C18 250x4.6mm, 5 column. Mobile phase containing a buffer and acetonitrile in the ratio of 60:40 v/v was pumped through the column at a flow rate of 1ml/min. Buffer used in this method was 0.1% OPA. Temperature of system was maintained at 30°C. The optimized wavelength for Lamivudine, Doravirine and Tenofovir disoproxil fumarate was 272.0 nm. Retention time of Lamivudine, Doravirine and Tenofovir disoproxil fumarate were found to be 2.314 min, 4.616 min and 3.196 min. % RSD of system precision for Lamivudine, Doravirine and Tenofovir disoproxil fumarate were found to be 1.0, 0.9 and 1.0 respectively. % RSD of method precision for Lamivudine, Doravirine Tenofovir were found to be 0.5, 0.7 and 0.5 respectively. % Recovery was obtained as 99.57%, 99.89% and 99.74% for Lamivudine, Doravirine and Tenofovir disoproxil fumarate respectively. LOD values obtained from regression equations of Lamivudine, Doravirine and Tenofovir disoproxil fumarate were 0.27 ppm, 0.09 ppm and 0.18 ppm, and LOQ values obtained from regression equations of Lamivudine, Doravirine and Tenofovir disoproxil fumarate were 0.82ppm, 0.28 ppm and 0.54ppm respectively. Regression equation of Lamivudine was y = 14959x + 1184, Doravirine was y = 28129x + 2766 and of Tenofovir was y = 17361x + 6030.
Downloads
How To Cite (APA)
Aneesha Kappen & Satya V (August-2024). Development and validation of a new RP-HPLC Method for the simultaneous estimation of Lamivudine, Doravirine and Tenofovir disoproxil fumarate in combined dosage form . INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 9(8), 243-312. https://ijnrd.org/papers/IJNRDTH00187.pdf
Issue
Volume 9 Issue 8, August-2024
Pages : 243-312
Other Publication Details
Paper Reg. ID: IJNRD_226834
Published Paper Id: IJNRDTH00187
Downloads: 000122009
Research Area: Pharmacy
Author Type: Indian Author
Country: Kasaragod DT, Kerala , India
Published Paper PDF: https://ijnrd.org/papers/IJNRDTH00187.pdf
Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRDTH00187
About Publisher
Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)
UGC CARE JOURNAL PUBLICATION | ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG
Copyright & License
© 2025 — Authors hold the copyright of this article. This work is licensed under a Creative Commons Attribution 4.0 International License. and The Open Definition.
You are free to share, adapt, and redistribute the material, provided proper credit is given to the original author. 🛡️ Disclaimer: The content, data, and findings in this article are based on the authors’ research and have been peer-reviewed for academic purposes only. Readers are advised to verify all information before practical or commercial use. The journal and its editorial board are not liable for any errors, losses, or consequences arising from its use.
Publication Timeline
Article Preview: View Full Paper
Call For Paper
IJNRD is a Scholarly Open Access, Peer-Reviewed, Refereed, and UGC CARE Journal Publication with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost, and Transparent Peer Review Journal Publication that adheres to the UGC CARE 2025 Peer-Reviewed Journal Policy and aligns with Scopus Journal Publication standards to ensure the highest level of research quality and credibility.
IJNRD offers comprehensive Journal Publication Services including indexing in all major databases and metadata repositories, Digital Object Identifier (Crossref DOI) assignment for each published article with additional fees, citation generation tools, and full Open Access visibility to enhance global research reach and citation impact.
The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse academic and professional fields. The journal promotes global knowledge exchange among researchers, developers, academicians, engineers, and practitioners, serving as a trusted platform for innovative, peer-reviewed journal publication and scientific collaboration.
Indexing Coverage: Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many other recognized academic repositories.
How to submit the paper?
By Our website
Click Here to Submit Paper Online
You can now publish your research in IJNRD. IJNRD is a Transparent Peer-Reviewed Open Access Journal Publication (Refereed Journal), aligning with New UGC and UGC CARE recommendations.
For more details, refer to the official notice: UGC Public Notice
Submit Paper Online
Important Dates for Current issue
Paper Submission Open For: November 2025
Current Issue: Volume 10 | Issue 11 | November 2025
Impact Factor: 8.76
Last Date for Paper Submission: Till 30-Nov-2025
Notification of Review Result: Within 1-2 Days after Submitting paper.
Publication of Paper: Within 01-02 Days after Submititng documents.
Frequency: Monthly (12 issue Annually).
Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.
Subject Category: Research Area
Call for Paper: More Details
Approval, Licenses and Indexing: More Details
